HOTH THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Hoth Therapeutics, Inc. - HOTHBusiness Wire • 04/27/23
HOTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Hoth Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 04/26/23
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyPRNewsWire • 03/08/23
Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting ActivityPRNewsWire • 02/16/23
Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZPRNewsWire • 02/08/23
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyPRNewsWire • 01/25/23
Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq RulesPRNewsWire • 01/03/23
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq RulesPRNewsWire • 12/30/22
Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyPRNewsWire • 12/29/22
Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001PRNewsWire • 12/01/22
HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITISPRNewsWire • 10/31/22
Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022PRNewsWire • 10/24/22
Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and StrokePRNewsWire • 09/20/22
Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy DisordersPRNewsWire • 09/06/22
Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor ConferencePRNewsWire • 08/12/22
Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's ProgramBenzinga • 07/12/22
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse ModelPRNewsWire • 07/12/22